



World Health
Organization



Gavi
The Vaccine Alliance



engagement
towards Zero by 30

Equitable and sustainable use of vaccines



Gavi's Vaccine Investment Strategy (VIS)

- Every five years, Gavi takes stock of available and expected vaccines to develop a new Vaccine Investment Strategy (VIS)
- WHO and other partners supported the case for including rabies post-exposure prophylaxis
- VIS 2018 for 2021–2025 approved support for human rabies vaccine for post-exposure prophylaxis, beginning in 2021
- Paused during COVID
- In May 2023, decision whether to unpause or reassess from the beginning
- Activating the roll out is essential to reach Zero by 30 making



<https://www.gavi.org/our-alliance/strategy/vaccine-investment-strategy>

Endemic diseases evaluation framework applied to rabies

Primary criteria <ul style="list-style-type: none">• Health Impact• Value for Money• Equity and Social Protection• Economic Impact• Global Health Security Impact	Secondary criteria <ul style="list-style-type: none">• Other health impact• Gavi comparative advantage• Implementation feasibility• Alternative interventions• Broader health system benefits
Costs	<ul style="list-style-type: none">• Vaccine cost• Operational costs• Additional implementation costs

Other endemic diseases: diphtheria, tetanus, pertussis, Hep B, cholera, meningococcus (multivalent), malaria

VIS Scope: inclusion and exclusion criteria

Inclusion Criteria

- ✓ Expected licensure by 2030
- ✓ Vaccines not currently in Gavi's portfolio, or incremental investments for Gavi-supported vaccines
- ✓ Stockpiles and stockpile-like investments
- ✓ Passive immunisation products (e.g., antibodies)

At investment case level:

- ✓ Diagnostics (if supports a vaccine; not a standalone investment)
- ✓ Learning agendas for vaccine investment support

Exclusion criteria

- ✗ Therapeutic vaccines that stimulate an immune response to combat existing disease (e.g., cancer)
- ✗ Animal vaccines
- ✗ Non-immunisation interventions and products as part of integrated control strategies (e.g., bed nets)

We need this investment to come close to Zeroby30

In 2022, 54 countries are eligible for Gavi support (Link)

- Rabies is endemic in 85% of them (n=46)
- No endemicity data is available for 11% (n=6)
- Only 4% (n=2) have no dog rabies

To make the decision Gavi with support of WHO will

- Conduct and external consultation to assess implementation status/plans & demand
- What is the updated country demand for these vaccines?
- How to roll out vaccines in a successful manner in current country/ global context?
What are the key needs for introduction and sustainability?



World Health
Organization



UAR Call to Action for



to invest



<https://www.unitedagainstrabies.org/news/rabies-experts-urge-gavi-to-implement-pep-investment/>
[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(22\)02487-4/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02487-4/fulltext)